CD70

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Retrieved on: 
Friday, April 26, 2024
Cancer, Safety, Regenerative medicine, TS, Metastasis, Trial of the century, Doctor of Philosophy, Development, Disease, CIRM, Autoimmune disease, Kite Pharma, Research and development, Patient, RCC, CD70, AACR, Clinical trial, Kidney cancer, Therapy, SAN, Pharmaceutical industry

It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.

Key Points: 
  • It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.
  • The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
  • Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2 regimen.
  • A more comprehensive data update from the ongoing trial is planned for later in 2024.

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Oncology, Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Cell, T-cell lymphoma, IND, Renal cell carcinoma, Neoplasm, CD70, Annual general meeting, Lung cancer, Vaccine

“ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform.

Key Points: 
  • “ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform.
  • ADI-270 is further enhanced with armoring to address suppressive tumor microenvironments and to address clearance by host T cells.
  • In preclinical studies, ADI-270 demonstrated enhanced functional persistence and potency, including unique contribution of innate anti-tumor immunity, compared to multiple clinically relevant benchmarks in cancers expressing CD70.
  • The preclinical findings indicate:
    ADI-270 demonstrated potent in vitro cytotoxicity against multiple CD70 positive tumor cell lines expressing varying levels of CD70.

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Clinical research, Health, B cell, Growth, Cell, Bone marrow, Infection, AML, Disease, Patient, Committee, Knowledge, Regulation, CD70, Cancer, EMA, IRIS, Business park, Acute myeloid leukemia, European, COMP, European Commission, Blood, Azacitidine, Safety, Haematopoietic system, Marketing, Acute leukemia, Medicine, Pharmaceutical industry

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Key Points: 


Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Sale, CD19, Lupus, RNA, EAP, LNP, Liver, Cardiovascular disease, CRISPR Therapeutics, CRSP, Therapy, Vertex Pharmaceuticals, Sickle cell disease, Autoimmunity, T1D, G&A, Bill, Partnership, Pharmacology, Guide, SCD, TDT, Pharmacokinetics, Clinical trial, ANGPTL3, United, Hypertriglyceridemia, Medicaid, Research, Human, CRISPR, Gene editing, CD70, Stem cell, ADC, Risk, Genetics, Patient, SLE, KSA, Moyamoya disease, Pharmaceutical industry

R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.

Key Points: 
  • R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses were $16.5 million for the fourth quarter of 2023, compared to $21.2 million for the fourth quarter of 2022.
  • Collaboration Expense: Collaboration expense, net, was $20.0 million for the fourth quarter of 2023, compared to $6.8 million for the fourth quarter of 2022.
  • Net Income (Loss): Net income was $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the fourth quarter of 2022.

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Retrieved on: 
Monday, January 8, 2024
LNP, Liver, Gene editing, Risk, Autoimmunity, Moyamoya disease, FDA, CRSP, SLE, Lupus, Stem cell, ANGPTL3, Pharmacology, CHMP, Kingdom, Guide, CRISPR Therapeutics, Vertex, PDUFA, Human, Pharmacokinetics, RNA, EMA, CRISPR, Therapy, Genetics, Vertex Pharmaceuticals, Bill, Patient, CD70, SCD, T1D, Sickle cell disease, Partnership, Hypertriglyceridemia, Research, Insulin, Diabetes, Hospital, Clinical trial, GMP, European Medicines Agency, Growth, Committee, CD19, TDT, Cardiovascular disease, Good, ADC, Pharmaceutical industry

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

Key Points: 
  • ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.
  • Exa-cel is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.
  • Vertex leads global development, manufacturing, regulatory and commercialization of CASGEVY with support from CRISPR Therapeutics.
  • CRISPR Therapeutics continues to focus on resource efficiency and return on invested capital as it advances multiple clinical programs across its pipeline.

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Retrieved on: 
Thursday, January 4, 2024
PIN, TS, EFS, Kite Pharma, Cancer, Conference, B-cell lymphoma, Disease, Steroid, CLL, Lymphocyte, First Line, CRS, Safety, News, Patient, Cyclophosphamide, MRD, AID, Cytokine release syndrome, Therapy, CF1, CD70, Biology, Westin St. Francis, Autoimmune disease, Renal cell carcinoma, SAN, Standard of care, Demand, Observation, RCC, CD19, Vaccine

“Until now, CAR T development has been defined by how autologous CAR Ts are made and used.

Key Points: 
  • “Until now, CAR T development has been defined by how autologous CAR Ts are made and used.
  • The standard of care after 1L treatment has been simply to “watch and wait” for the disease to relapse.
  • ALPHA3 builds on the growing understanding that administration of CAR T therapies to patients with low disease burden improves both safety and efficacy outcomes.
  • The 2024 Platform Vision Conference Call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Telephone, Initiate, Myositis, Tumor microenvironment, Risk, Probability, IND, Autoimmunity, FDA, Cytokine release syndrome, CD20, Renal cell carcinoma, Scleroderma, Tissue, Cmax, Cancer, TGF, Tropism, NHL, Patient, CD19, AUC, Safety, Lupus nephritis, CD70, MCL, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.
  • “In 2024, we aim to make significant strides across our pipeline of differentiated gamma delta T cell therapies through our strategic and disciplined approach,” said Chen Schor, President and Chief Executive Officer at Adicet Bio.
  • Initiate Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024.
  • The Company remains on track to provide an ADI-001 clinical update in the second half of 2024.

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Cellular, Transplant, Exposition, CD70, Cytokine release syndrome, CRi, Myelodysplastic syndrome, Molecular Partners, Society, Infrared spectroscopy correlation table, ASH, DARPin, CD123, Poster, DRS, Safety, Tetra, AML, Therapy, Pharmaceutical industry

These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.

Key Points: 
  • These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.
  • “We are excited to share these initial data for MP0533, where we see antileukemic activity, already at these low doses, with a favorable safety profile.
  • We look forward to the continuation of this study and evaluating the full potential of MP0533 for patients,” said Patrick Amstutz, CEO of Molecular Partners.
  • Details of the poster presenting these results from the ongoing Phase 1/2a trial of MP0533 at the 65th ASH Annual Meeting and Exposition can be found below.